Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles, California 90095


The goal of this study is to evaluate the effectiveness and safety of field-initiated magnesium sulfate in improving the long-term functional outcome of patients with acute stroke.

Study summary:

Stroke is the third leading cause of death and the leading cause of adult disability in the United States. Each year, more than 750,000 Americans suffer a symptomatic stroke. Currently, rt-PA is the only approved treatment for acute ischemic stroke; however, its usefulness is limited because most patients cannot reach medical attention within the necessary 3-hour time window. In addition, rt-PA cannot be given in the field because it is contraindicated for treatment of patients with brain hemorrhage. The purpose of this multi-center, randomized, double-blind trial is to demonstrate that paramedic initiation of the neuroprotective agent magnesium sulfate in the field is an effective and safe treatment for acute stroke. This study will analyze magnesium sulfate, an experimental therapy for stroke, versus placebo among ambulance-transported patients with acute stroke. This trial will also demonstrate that paramedics can safely, effectively, and rapidly start neuroprotective therapies for stroke.


Inclusion Criteria: - Suspected stroke identified by the Los Angeles Prehospital Stroke Screen - Age 40-95, inclusive - Last known well time within 2 hours of treatment initiation - Deficit present for >/= 15 minutes Exclusion Criteria: - Coma - Rapidly improving neurologic deficit - Pre-existing neurologic, psychiatric, or advanced systemic disease that would confound the neurological or functional outcome evaluations - SBP < 90 or > 220 - Known severe renal dysfunction (on dialysis or known chronic creatinine > 3.0) - Severe respiratory distress (O2 sat < 90% or respiratory rate < 12 or >/= 24) - Known second or third degree heart block with no pacemaker in place - Major head trauma in the last 24 hours - Recent stroke within prior 30 days - Patient unable to give informed consent and no available on scene consent or assent provider



Primary Contact:

Principal Investigator
Jeffrey Saver, M.D.
UCLA School of Medicine, Study Overall Principal Investigator

Backup Contact:


Location Contact:

Los Angeles, California 90095
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.